return flight

Here's how to watch the historic NASA/SpaceX splashdown in Houston

NASA astronauts Bob Behnken and Doug Hurley are coming home. Photo courtesy of NASA

On May 30, the world watched a historic — and uplifting — moment in space travel, as NASA astronauts Robert Behnken and Douglas Hurley blasted off from Earth in a commercial craft created by Elon Musk's SpaceX. The NASA/SpaceX Dragon Endeavour flight was the first launch with astronauts of the SpaceX Crew Dragon spacecraft and Falcon 9 rocket to the International Space Station as part of the agency's Commercial Crew Program.

The SpaceX Demo-2 launch was a success: the duo orbited Earth and eventually boarded the International Space Station; Behnken and Hurley have been stationed there since.''

Now, space fans can watch the return of the NASA/SpaceX Demo-2 test flight, which is scheduled for 1:42 pm CST on Sunday, August 2. The splashdown represents the first return of a commercially built and operated American spacecraft carrying astronauts from the space station, according to NASA. The historic return signifies the close of a mission designed to test SpaceX's human spaceflight system, including launch, docking, splashdown, and recovery operations.

The ever-popular Space Center Houston (the official visitor center of NASA's Johnson Space Center) will stream the live splashdown in a socially distanced event. Visitors can engage in interactive, pop-up science labs to learn about the splashdown process, the specially crafted spacesuits, and more.

To make it a full day of exploration, guests can walk underneath a flown SpaceX Falcon 9 rocket, which is the only Falcon 9 on public display outside of SpaceX's headquarters, and is the same type of rocket used in the Demo-2 mission.

Guests can also take a tour of the Independence Plaza exhibit and walk inside a shuttle replica mounted on top of the historic shuttle carrier aircraft NASA 905. Myriad other experiences await; safety protocols will be in place.

Meanwhile, NASA will broadcast the splashdown coverage on NASA TV and the agency's website beginning early morning on August. 1, with coverage lasting through splashdown on August 2.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted